comparemela.com

Latest Breaking News On - Mva investors llc - Page 1 : comparemela.com

Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells 63,000 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Mva Investors, Llc sold 63,000 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $7.24, for a total transaction of $456,120.00. Following the completion of the transaction, the insider now owns 420,524 shares […]

Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 63,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $7.24, for a total value of $456,120.00. Following the completion of the transaction, the insider now owns 420,524 […]

Q2 2024 EPS Estimates for Tango Therapeutics, Inc. (NASDAQ:TNGX) Cut by Analyst

Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) – Stock analysts at HC Wainwright lowered their Q2 2024 earnings per share estimates for Tango Therapeutics in a research note issued to investors on Tuesday, May 28th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.36) per share for the quarter, […]

HC Wainwright Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $13.00

Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target cut by HC Wainwright from $16.00 to $13.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2024 earnings at ($0.36) EPS, Q3 2024 earnings […]

HC Wainwright Trims Tango Therapeutics (NASDAQ:TNGX) Target Price to $13.00

Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target trimmed by HC Wainwright from $16.00 to $13.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2024 earnings at ($0.36) EPS, Q3 2024 earnings at […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.